A Japanese Multicenter Database Study of Retroperitoneal Sarcoma: Outcomes of Patients Receiving Eribulin Therapy
Asia-Pacific Journal of Clinical Oncology · 2026
DOI: 10.1111/ajco.70080 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2026. Verfasst von Makito Miyake und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Nara Medical University, Kashihara, Nara, Japan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Furans, Ketones, Retroperitoneal Neoplasms. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Aim
Clinical evidence on disease characteristics and outcomes of retroperitoneal sarcoma (RPS) remains limited. Although eribulin was approved for soft tissue sarcomas in Japan in 2016, real‐world data on its use for advanced RPS are scarce. We investigated treatment patterns and survival outcomes of patients with RPS, with a particular focus on those receiving eribulin.
Methods
The database included 118 patients pathologically diagnosed with RPS between January 2000 and August 2025. Clinicopathologic data, including inflammation/nutrition markers and survival outcomes, were analyzed.
Results
Among them, 102 (86%) underwent surgical resection of the primary tumor, with a median recurrence‐free survival of 20 months and a median overall survival of 9.2 years. Well‐differentiated liposarcoma, dedifferentiated liposarcoma, leiomyosarcoma, and undifferentiated pleomorphic sarcoma were the most frequent histologic subtypes. Non‐well‐differentiated liposarcoma histology, Stage IIIA−IIIB, lower C‐reactive protein–albumin–lymphocyte index, and higher modified neutrophil–platelet score were associated with poor postoperative prognosis. Of 44 patients with unresectable RPS who received systemic therapy, 23 (52%) were treated with eribulin. In this group, complete response, partial response, and stable disease rates were 4.3%, 26%, and 35%, respectively. The most common adverse events were decreased neutrophil count (40%), peripheral neuropathy (30%), and dysgeusia (20%). Multivariate analysis showed that non‐use of eribulin and undifferentiated pleomorphic sarcoma were independently associated with worse survival in unresectable disease.
Conclusion
We separately described outcomes and treatment patterns of patients with resectable and unresectable RPS. Our findings suggest that eribulin should be considered a treatment option for unresectable RPS in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Nara Medical University, Kashihara, Nara, Japan.
- Department of Urology, Nara Prefecture General Medical Center, Nara, Nara, Japan.
- Department of Urology, Nara City Hospital, Nara, Nara, Japan.
- Department of Urology, Saiseikai Chuwa Hospital, Sakurai, Nara, Japan.
- Department of Urology, Yamatotakada Municipal Hospital, Yamatotakada, Nara, Japan.
- Department of Urology, Matsusaka Chuo General Hospital, Matsusaka, Mie, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Miyake, M., Oda, Y., Nishimura, N., Yoshikawa, M., Sakamoto, K., Matsumura, Y., Tomioka, A., Iemura, Y., Kuwada, M., Iida, K., Iwamoto, T., Maesaka, F., Toyoshima, Y., Fujii, T., Fujimoto, K., & Nara Urological Research and Treatment Group (NURTG) (2026). A Japanese Multicenter Database Study of Retroperitoneal Sarcoma: Outcomes of Patients Receiving Eribulin Therapy. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.70080
Vancouver
Miyake M, Oda Y, Nishimura N, Yoshikawa M, Sakamoto K, Matsumura Y, et al. A Japanese Multicenter Database Study of Retroperitoneal Sarcoma: Outcomes of Patients Receiving Eribulin Therapy. Asia-Pacific Journal of Clinical Oncology. 2026. doi:10.1111/ajco.70080
BibTeX
@article{Miyake2026,
author = {Miyake, Makito and Oda, Yuki and Nishimura, Nobutaka and Yoshikawa, Motokiyo and Sakamoto, Keiichi and Matsumura, Yoshiaki and Tomioka, Atsushi and Iemura, Yusuke and Kuwada, Masaomi and Iida, Kota and Iwamoto, Takashi and Maesaka, Fumisato and Toyoshima, Yuta and Fujii, Tomomi and Fujimoto, Kiyohide and Nara Urological Research and Treatment Group (NURTG), Nara Urological Research and Treatment Group (NURTG)},
title = {A Japanese Multicenter Database Study of Retroperitoneal Sarcoma: Outcomes of Patients Receiving Eribulin Therapy},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
doi = {10.1111/ajco.70080}
}
EUVIMED